Pembrolizumab Regimens Approved in EU for Frontline PD-L1+ HNSCC

November 20, 2019 – The European Commission has approved pembrolizumab as a monotherapy or in combination with platinum and 5-FU chemotherapy for the frontline treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) and PD-L1 expression (composite positive score [CPS] ≥1) on their tumors. The approval is based on results from the phase III KEYNOTE-048 trial, in which single-agent pembrolizumab … (leggi tutto)